TerminatedPHASE2, PHASE3NCT00368264

TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )

Studying Systemic lupus erythematosus

Last synced from ClinicalTrials.gov May 17, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Medical University of Vienna
Principal Investigator: Josef S Smolen, MD, M.D
Head, Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Austria
Intervention: infliximab(drug)
Enrollment: 1 enrolled
Eligibility: 18 years · All sexes
Timeline: 2006 – 2009

Study locations (9)

Departments of Rheumatology, Internal Medicine, Medical University of Graz, Graz, Austria
Rheumatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria
Internal Medicine II, Hietzing Hospital, Vienna, Austria
Rheumatology, Charite, Berlin, Germany
Rheumatology, University of Düsseldorf, Düsseldorf, Germany
Internal Medicine III, University of Erlangen, Erlangen, Germany
Clinical Immunology, Groningen University Hospital, Groningen, Netherlands
Leiden University Medical Center, Netherlands, Leiden, Netherlands
Nephrology, University of Nymegen, Netherlands, Nijmegen, Netherlands

Collaborators

Hospital Hietzing · Medical University of Graz · Charite University, Berlin, Germany · University of Erlangen-Nürnberg · Heinrich-Heine University, Duesseldorf · University Medical Center Groningen · Leiden University Medical Center · Radboud University Medical Center

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00368264 on ClinicalTrials.gov

Other trials for Systemic lupus erythematosus

Additional recruiting or active studies for the same condition.

See all trials for Systemic lupus erythematosus →

← Back to all trials